Who Lobbies on Health Care, How Much, and on What

Health care reported more federal lobbying than any other part of the economy in 2025. Drugmakers, insurers and hospitals spent the most, but doctors, nurses, AARP and patient groups lobby on the same bills, and many patient groups take money from companies with a stake in those bills. What the disclosures show for 2025 and 2026, how to read them, what they leave out, and what the research says lobbying buys.

The short version

Federal lobbying reports show who paid to press their case on health care, how much, and which bills they named, but not which side they took or whether it worked. Health care reported about $878 million in 2025, more than any other part of the economy. That is roughly its share of the economy and under 2 cents for every $100 spent on care. Drugmakers, insurers and hospitals spent the most, but doctors, AARP and patient groups lobby on the same bills. Many patient groups take money from companies with a stake in those bills. And the industries often oppose each other: hospitals against insurers on site-neutral payment, drugmakers against PBMs, drugmakers against hospitals on 340B. The reports leave out advertising, grants to allied groups, state lobbying and campaign money. Research finds lobbying changes outcomes less than the totals suggest, but the stakes are large enough that small shifts in the odds pay off.

New articles and charts arrive in one short email on Monday mornings. Get the weekly digest

The analogy

The sign-in sheet at the front desk of a big office building. Each visitor writes down whom they represent, which offices they went to and roughly what about, and what the visit cost. A visitor sent by a firm signs in for the firm, and the client signs in too, so adding up every line counts some visits twice. The sheet shows who comes often and who spends the most getting in the door. It doesn't record what was said, which side the visitor was on, or whether anyone changed their mind, and it says nothing about the billboard across the street, the letters a visitor got people back home to send, or the visits to the state capitol down the road.

This page is a sequel to who gains and who pays in health care, which covers what is at stake in each option. Figures below come from reports retrieved from the Senate's LDA.gov on November 1, 2026, and cover 2025 and the first nine months of 2026.

How to read a lobbying report

Under the Lobbying Disclosure Act, a person paid to lobby must be registered once they make more than one lobbying contact for a client and spend at least a fifth of their time for that client on lobbying over three months (2 U.S.C. 1602). A lobbying contact is a meeting, call, email or letter to a member of Congress, congressional staff or a senior executive-branch official about legislation, a rule, a program or a nomination; testimony, comments filed on a proposed rule and material sent to the public don't count. Since January 2025, a firm needn't register for a client that pays it $3,500 a quarter or less, and an organization with its own lobbyists needn't register if it spends $16,000 a quarter or less (House and Senate guidance).

Every quarter, each registrant files a report for each client: what was spent, rounded to the nearest $10,000 (under $5,000 is just a box to check), the general issue areas and the specific bills, rules and programs, the chambers and agencies contacted, and the lobbyists who did the work. Reports are due 20 days after the quarter ends. Third-quarter reports were due October 20, 2026, and a few, such as the American Academy of Pediatrics', hadn't appeared by November 1. Fourth-quarter reports are due January 20, 2027.

Two kinds of filers, one count. An organization with its own lobbyists, such as PhRMA, the American Hospital Association or AARP, reports its total lobbying expenses, and the guidance requires that figure to include what it paid outside firms. The firms file too, reporting what each client paid them, so adding both counts the same dollars twice. PhRMA's own reports add up to $37.9 million for 2025, and the 31 outside firms it hired reported $7.1 million from PhRMA, money already inside PhRMA's figure. This page follows OpenSecrets' method: for an organization that files its own reports, its reported expenses; for one that only hires firms, the sum of what the firms reported. An amended report replaces the original, which matters: the AMA first reported $513,000 for the second quarter of 2026 and corrected it to $5.13 million. Reports marked under $5,000 count as zero.

Not every figure measures the same thing. A filer may report under the act's own definition or under one of two tax-law definitions, which add state lobbying and grassroots campaigns aimed at the public but count contacts with fewer executive-branch officials, so the two kinds of figures aren't strictly comparable. Eighteen of the 93 organizations below use a tax-law definition, among them the American Medical Association, the Pharmaceutical Care Management Association and the Biotechnology Innovation Organization; the tables mark them.

Which organizations, in which group. The groups are ours, and each organization goes in one by what it is, its members or its business, not by what it lobbied on. We looked up the largest national organizations in each group by name: the main trade associations, 14 large drug companies, and the largest insurers, hospital systems, medical societies, nursing groups, patient groups and single-payer advocates that file. Name variants on the reports were matched by hand, including subcontracts filed "on behalf of" a client, and organizations that merely shared a word with the search were left out. Subsidiaries that report under a different name aren't added, which understates a few companies: UnitedHealth Group's figure leaves out Medica Healthcare Plans and Amedisys, for example. The three largest pharmacy benefit managers belong to insurers (CVS Caremark to CVS Health, Express Scripts to Cigna, Optum Rx to UnitedHealth Group), and none filed under its own name in 2025 or 2026; CVS Health and Cigna report for themselves "and subsidiaries," and UnitedHealth Group as the parent company. AARP, unions and a few advocacy groups lobby on much besides health; their figures are everything they reported.

Checked against OpenSecrets. OpenSecrets publishes totals built from the same reports under a license this site can't reuse, so they serve here only as a check. For AARP, AHIP, PCMA, the Federation of American Hospitals and HCA, ours match OpenSecrets' 2025 figures to the dollar, and PhRMA and the AMA are within 3%. For UnitedHealth Group and Kaiser Permanente, OpenSecrets is 6% to 7% higher because it counts affiliates we left out, and its figure for the American Hospital Association, $32.0 million, adds 25 state hospital associations and affiliates to the association's own $25.5 million.

Whose side. Reports list bills and topics, not positions. A hospital group and an insurers' group can name the same bill in the same quarter while pushing in opposite directions. A few filers say which side they're on anyway (National Nurses United wrote "Support Medicare for All Act"); the positions below otherwise come from each organization's own statements. The Senate's terms for using its data ask for this sentence: the Senate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.

Who spent what

Group (organizations)2025Jan.–Sept. 2026
Drugmakers (17)$168.0 million$131.4 million
Insurers (11)$76.4 million$58.9 million
Hospitals and health systems (15)$57.6 million$38.1 million
Physicians (12)*$40.2 million$31.7 million
Patient groups (23)$23.9 million$15.6 million
AARP (1), all issues$20.9 million$12.5 million
Pharmacy benefit managers (1)*$13.7 million$9.5 million
Device makers (4)$11.6 million$9.6 million
Nurses and health unions (5)$5.8 million$4.7 million
Consumer and single-payer groups (4)$0.5 million$0.4 million
All 93 organizations$418.8 million$312.4 million

*Includes figures reported under a tax-law definition: about three-quarters of the physicians' total and all of the PBM figure. Totals are de-duplicated as described above. Source: LDA.gov reports, retrieved November 1, 2026.

Reported federal lobbying by group, 2025

Millions of dollars, the 2025 column of the table above; the physicians' and PBM figures include amounts reported under a tax-law definition. Source: LDA.gov reports, de-duplicated as described above

The largest in each group in 2025: PhRMA ($37.9 million), then Amgen ($13.3 million) and Pfizer ($12.6 million); AHIP ($17.2 million) and UnitedHealth Group ($11.7 million); the American Hospital Association ($25.5 million) and the Children's Hospital Association ($6.5 million); the American Medical Association ($23.1 million, under a tax-law definition); the American Cancer Society Cancer Action Network ($9.1 million) and the Alzheimer's Association ($4.0 million); Medtronic ($4.7 million) and AdvaMed ($3.8 million); the American Association of Nurse Anesthesiology ($1.9 million) and the American Association of Nurse Practitioners ($1.7 million); and Public Citizen ($350,000, on every issue it works on).

The totals reflect our choices of whom to count. The insurer row has the Blue Cross Blue Shield Association but not the 30-odd independent Blue plans, which OpenSecrets puts together at $28.0 million; the hospital row leaves out state hospital associations; and the single-payer row leaves out the unions and advocacy groups that also lobbied for Medicare for All (see below). The comparisons that follow inherit those choices.

The 93 organizations reported 4% less in the first nine months of 2026 than in the same months of 2025, when Congress was writing the reconciliation law. Hospitals were down 12%, patient groups 16% and AARP 20%; drugmakers, insurers and physicians were about level.

Against the whole. OpenSecrets, which sorts every client, counts $878 million of health lobbying in 2025 from more than 2,000 clients, the most of any part of the economy, out of a record $5.08 billion in all federal lobbying: about 17%. (OpenSecrets files AHIP and most Blue Cross Blue Shield lobbying under insurance.) Health care was 18% of the economy in 2024, when the country spent $5.3 trillion on it, so its share of lobbying is roughly its share of the economy. Measured against the money at stake, the amounts are small: the health total is about 1.7 cents for every $100 of health spending. Against each part of the system's 2024 revenue (Hartman and others), the 17 drugmaker organizations here reported about 3.6 cents per $100 of retail prescription drug spending ($467 billion, a measure that leaves out drugs given in hospitals and clinics); the 11 insurer organizations about 2.5 cents per $100 of what insurance costs beyond the claims it pays ($306 billion of administration, taxes and profit or loss); and hospitals and physicians each about a third of a cent per $100 of hospital care ($1.63 trillion) and of physician and clinical services ($1.11 trillion).

Patient groups are not small spenders next to one another, only next to industry. The American Cancer Society Cancer Action Network's $9.1 million was more than all but seven of the drugmaker organizations on the list. AARP's $20.9 million was close to the AMA's $23.1 million, though the AMA's figure uses the broader tax-law definition and AARP's doesn't. The 23 patient groups together reported about a seventh of what the 17 drugmaker organizations did.

What they lobbied on

The table counts how many organizations in each group named each topic in at least one report from January 2025 through September 2026, by searching the bills and issues they listed. The columns: Medicare for All; the 2025 reconciliation bill (H.R. 1); its Medicaid changes, meaning work requirements, provider taxes, eligibility checks or spending; the enhanced marketplace premium credits; pharmacy benefit managers; drug prices; site-neutral payment; and the 340B drug discount program. The table shows attention, not position, and a report that names a bill once counts the same as one that names it every quarter.

Group (organizations)Medicare for AllReconcil­iation billMedicaid changesPremium creditsPBMsDrug pricesSite-neutral340B
Drugmakers (17)017021717016
Insurers (11)111388833
Hospitals (15)01288281011
Physicians (12)211233620
Patient groups (23)018121110913
AARP (1)01111100
PBM association (1)01001100
Device makers (4)03000000
Nurses and unions (5)25420100
Consumer, single-payer (4)33121210

Medicare for All. At least 18 organizations named it in a report: National Nurses United, SEIU, the UAW, the American Federation of Teachers and a stagehands' union; Public Citizen, Social Security Works, Physicians for a National Health Program, MoveOn Civic Action and a few other advocacy groups; and AHIP, the American Medical Association, the American Society of Anesthesiologists, the U.S. Chamber of Commerce and Delta Dental's association. Supporters often said so in the report: Physicians for a National Health Program and Social Security Works listed the bills "in support", and SEIU described meeting Rep. Pramila Jayapal's office about reintroducing the bill. AHIP, the AMA, the anesthesiologists, the Chamber and Delta Dental's association named it without stating a side. Elsewhere, the AMA's policy says single payer is "not in the best interest of the country", reaffirmed in 2026, and AHIP called a complete overhaul the wrong approach in 2023 testimony against an Oregon single-payer bill. National Nurses United said in April 2025 it was proud to continue its support. The best-known industry campaign against it, the Partnership for America's Health Care Future, filed no lobbying reports in 2025 or 2026; see below. The bills are S. 1506 and H.R. 3069 of the 119th Congress.

The 2025 reconciliation law and Medicaid. Nearly everyone named the reconciliation bill, which carried changes for drugmakers, insurers, hospitals and patients alike, so the narrower column is the telling one: hospitals, insurers, unions, AARP and 12 of the 23 patient groups named its Medicaid changes, often in plain terms (the American Cancer Society Cancer Action Network wrote that it worked "to protect Medicaid from cuts"). The American Hospital Association said Congress had enacted "cuts of nearly a trillion dollars to the Medicaid program"; the AMA called it a sad and unnecessarily harmful day for patients. Supporters made the opposite case. The Foundation for Government Accountability urged passage for moving able-bodied adults "from welfare to work", and the Paragon Health Institute, a conservative health-policy group, called the provider-tax arrangements the law limits legalized "money laundering", in which providers pay a state tax, the state draws federal matching money on it, and the providers are paid back with more.

The enhanced premium credits. Insurers, hospitals, AARP and 11 patient groups named the expanded marketplace credits that expired at the end of 2025; only 2 of the 17 drugmaker organizations did. AHIP said keeping them would "bring immediate relief to millions"; the American Hospital Association urged Congress to extend them. On the other side, the Paragon Health Institute argued that Congress "should let Biden's COVID credits expire", because they were temporary, costly and drew improper enrollment. The arguments in full are in what health insurance costs.

Pharmacy benefit managers. All 17 drugmaker organizations and 8 of the 11 insurer organizations, which include the parents of the largest PBMs, named PBMs, as did 10 patient groups. The February 2026 spending law barred PBMs in Medicare Part D from pay tied to drug prices and, for employer-plan contracts starting 30 months after enactment, required them to pass rebates through. PhRMA said that for too long PBMs "have profited from medicines with little transparency"; the PBMs' association told Congress the mandates were unnecessary and harmful to affordability, and said in a memo that the law would push drug prices higher and was the product of years of drugmaker campaigning.

Drug prices. Every drugmaker organization named drug pricing, meaning Medicare's price negotiation, the administration's most-favored-nation pricing, or bills to change either. PhRMA calls government price setting the wrong policy for America; AARP said the second round of negotiated prices would bring "meaningful relief to millions of people on Medicare". Advocates split. Patients for Affordable Drugs opposes the EPIC Act, which would give pills the same 13 years before negotiated prices apply that biologic drugs get, saying it would "hand pharmaceutical companies four more years" of prices set without negotiation; the Partnership to Fight Chronic Disease, a coalition whose partners range from patient and community groups to PhRMA, calls the shorter timeline for pills a significant disincentive to developing them.

Site-neutral payment. Paying the same for a routine service whether a hospital-owned clinic or an independent office provides it was named by 10 of the 15 hospital organizations, three insurer organizations, the AMA, the American College of Physicians, Blood Cancer United and Families USA. The American Hospital Association asks Congress to reject what it calls billions in Medicare cuts, arguing that hospital clinics treat sicker and poorer patients under stricter rules; AHIP says site-neutral payment would "help level the playing field on prices". Congress hasn't passed a broad version, but Medicare has extended it by rule, to drug administration at off-campus hospital clinics from 2026, and the American Hospital Association is opposing a proposal to add imaging without contrast in 2027.

340B and doctors' pay. Two topics that who gains and who pays in health care doesn't cover show where industries face each other. The 340B program requires drugmakers to sell at a discount to hospitals and clinics that serve many low-income patients; 16 of the 17 drugmaker organizations and 11 of the 15 hospital organizations named it, PhRMA has run ads urging Congress to change it, and the American Hospital Association has opposed a rebate model drugmakers favor. And 11 of the 12 physician groups named Medicare's payments to doctors, where the AMA asks for a permanent yearly update tied to the cost of running a practice.

Patient groups, and who pays for them

Patient groups lobby on the same bills as everyone else, for less, and they spent most of their attention on coverage: 18 of the 23 named the reconciliation bill and 11 the premium credits, against 9 that named drug pricing. Many also take money from companies whose products and prices are at stake, which is one reason "industry against patients" is the wrong way to read the first table.

What the research found. In a survey conducted in 2013–14 and published in JAMA Internal Medicine in 2017, 67% of the patient advocacy organizations that answered had taken industry money in their last fiscal year, and 12% got more than half their funding from industry; most groups in the survey were small, with a median budget of about $300,000, and 8% said they had felt pressure to conform their positions to a corporate donor's. A study of the 104 largest groups, in the New England Journal of Medicine the same year, found that 83% reported industry support, 39% had a current or former industry executive on the board, and only 17% said how much of their revenue came from industry. KFF Health News found that in 2015, 14 large drugmakers gave patient groups at least $116 million, nearly twice the $63 million they spent on federal lobbying that year. A 2020 review of 26 studies found that the few studies that compared positions found funded groups generally sided with their sponsors.

What the groups disclose. Disclosure is voluntary, and it varies. Donors' names on the tax schedule that lists them are blacked out on public copies.

GroupLobbying, 2025Jan.–Sept. 2026What it discloses about industry funding
American Cancer Society Cancer Action Network$9.1 million$5.3 millionThe American Cancer Society lists corporate partners by cumulative-giving tier (dollar ranges), without exact amounts or an industry share
Alzheimer's Association$4.0 million$3.7 millionDrug, biotech and diagnostics companies gave $7.2 million of $409.5 million in fiscal 2025 (1.8%), with a list by company
American Heart Association$1.6 million$770,000Drug, biotech and device companies about 5% of $1.4 billion in fiscal 2025, with a list of the companies
American Lung Association$770,000$350,000Corporate support $8.5 million of $163.2 million in fiscal 2025 (5.2%), not broken out by industry
Cystic Fibrosis Foundation$760,000$690,000Sold its royalty rights on Vertex's cystic fibrosis drugs, which it helped fund, to Royalty Pharma for $3.3 billion in 2014
American Diabetes Association$350,000$260,000$24.8 million from drug and device makers in 2023 (unaudited), about 17% of revenue, listed by company
National Organization for Rare Disorders$200,000*$200,000*About 100 companies plus PhRMA and BIO on its corporate council, without amounts
National Health Council$100,000*$60,000*Members include PhRMA, BIO, AHIP, Cigna, AdvaMed and drug and device makers; PhRMA gave it $390,000 in 2024
Partnership to Fight Chronic Disease$290,000$210,000Doesn't disclose funders; its roughly 100 listed partners range from patient groups and unions to PhRMA and BIO
Patients for Affordable Drugs Now$240,000$80,000Takes no money from anyone who profits from prescription drugs; Arnold Ventures, a philanthropy, gave $455,000 in 2024
Alliance for Patient Access$80,000$60,000Lists 29 supporters, all drugmakers, without amounts

*Reports under a tax-law definition. Lobbying: LDA.gov, retrieved November 1, 2026; funding: each group's disclosure, linked below.

The American Diabetes Association lists each company's gifts: $24.8 million from drug and device makers in 2023, in a draft it marks unaudited, led by Eli Lilly at $7.3 million, against $144.7 million in total revenue. The Alzheimer's Association reports $7.2 million from drug, biotech and diagnostics companies in fiscal 2025, with a list by company; the American Heart Association reports about 5% of its revenue from drug, biotech and device companies; and the American Lung Association $8.5 million in corporate support. The Cystic Fibrosis Foundation helped pay for the research behind Vertex's drugs and, through an affiliate, sold its royalty rights on them to Royalty Pharma for $3.3 billion. The American Cancer Society lists its corporate partners by giving tier. Others name supporters without amounts: the National Organization for Rare Disorders' corporate council, the Alliance for Patient Access's list of supporters, the National Health Council's members (PhRMA's 2024 grant to the Council is on PhRMA's tax return), and the Partnership to Fight Chronic Disease's partners, a list it says doesn't imply support for all of its policy positions. Patients for Affordable Drugs, whose affiliate files the lobbying reports, says it takes no money from anyone who profits from developing or distributing prescription drugs; the funders it lists for 2024 are led by Arnold Ventures, a philanthropy that also funds research and advocacy for lower health prices, at $455,000, about half the total listed.

Much of the industry money comes from individual companies, which disclose it unevenly: a 2019 study found that only 6 of the 10 largest drugmakers disclosed their payments to patient groups.

AARP is its own case. It is a membership organization for people over 50, the fourth-largest spender on this page, and most of its revenue comes from licensing its name. In 2024 it reported $962 million in royalties from health products and services, mostly insurance sold under its brand, out of $1.9 billion in operating revenue, against $289 million in dues. That year it also received a one-time payment of $9.1 billion from a group health insurer for an exclusive license, which it counts as revenue over 12 years; Axios identified the insurer as UnitedHealthcare, and an AARP spokesperson told Axios the deal runs through a separately managed subsidiary that has no input on AARP's policymaking. AARP's positions don't line up with any one industry: it backs Medicare drug price negotiation, which PhRMA opposes, and site-neutral payment, which hospitals oppose and insurers support.

Industry isn't one side either. Hospitals and insurers are on opposite sides of site-neutral payment, drugmakers and PBMs on opposite sides of PBM reform, and drugmakers and hospitals on opposite sides of 340B; hospitals, insurers, AARP and consumer groups were on the same side of extending the premium credits, and advocates who describe themselves as speaking for patients were on both sides of the EPIC Act.

What the reports leave out

Persuading the public. Advertising aimed at voters isn't lobbying under the act, even when it urges people to call Congress. The American Hospital Association ran a seven-figure ad campaign against Medicaid cuts in June 2025, and the ad tracker AdImpact counted $75.3 million in ads about the reconciliation bill from April to early July 2025, about $40 million for it and $35 million against.

Money given to others. Grants to coalitions, think tanks and advocacy groups appear on tax returns, not lobbying reports. On its 2024 return, PhRMA reported $43.3 million in grants, including $6.8 million to We Work for Health, an advocacy group; $4.0 million to American Action Network, a center-right advocacy group; $300,000 to the Partnership for America's Health Care Future; and $200,000 each to the American Action Forum, a center-right think tank, the American Legislative Exchange Council, a conservative organization of state legislators, and the Third Way Foundation, a center-left think tank. The Partnership, founded in 2018 by the Federation of American Hospitals, AHIP, the Blue Cross Blue Shield Association, PhRMA and the AMA (the AMA left in 2019), opposes Medicare for All, a Medicare buy-in and a public option, and lists more than a hundred members, from hospital chains to chambers of commerce. It filed no lobbying reports in 2025 or 2026.

The broader definition. On the same tax return, PhRMA reported $228.6 million of lobbying and political spending its members can't deduct, under the tax law's definition, which includes state lobbying, grassroots campaigns and political activity. Its federal lobbying reports for 2024 came to $31.7 million.

Campaign contributions go to the Federal Election Commission and state lobbying to each state; both are outside this page. Many health fights happen in statehouses: pharmacy benefit rules, which professionals may do what, and Medicaid itself, which states run.

Lobbying below the lines. Advisers who spend less than a fifth of their time for a client on lobbying, or who plan strategy without making contacts themselves, needn't register.

How accurate the reports are. Each year the Government Accountability Office checks a sample of reports against filers' records. In its June 2026 review, 94% of reports could document their income or expenses and 87% could document every issue area they listed; no civil or criminal enforcement actions under the act were taken in 2025. The law doesn't require filers to keep records, and GAO doesn't check whether a report covers all of a filer's lobbying.

What the research says lobbying buys

Less than the totals suggest, and more than nothing. In the largest study of lobbying outcomes, Frank Baumgartner and four coauthors followed 98 randomly chosen issues and found that about 60% of lobbying campaigns produced no change in policy, that the status quo usually won, and that the resources on each side explained less than 5% of who prevailed. Studying energy bills, Karam Kang found that lobbying raised the chance a policy was enacted by a statistically significant but very small amount, and that it paid anyway, with average returns above 130%, because the policies were worth so much.

Health care has examples on both sides. The drug and health-products industry spent a record $372 million on lobbying in 2022, and the Inflation Reduction Act, the most lobbied bill that year, passed with Medicare drug price negotiation in it. The PBM changes in the February 2026 spending law passed over the PBMs' objections. On the other side, hospitals whose House members voted for the 2003 Medicare law were more likely to receive a special Medicare payment increase, known as a Section 508 waiver, which raised local health spending; the hospitals that got them formed a coalition, lobbied to extend them, and won extensions. Some influence never appears as lobbying: Medicare sets doctors' fees with advice from a committee convened by the AMA, and in one study, specialties whose societies were more closely aligned with that committee got about 10% higher fees per standard deviation of alignment. Another found that the FDA approved drugs faster for diseases with wealthier advocacy groups.

Where the analogy breaks

Not every visitor signs in. The thresholds let occasional lobbyists, and strategists who stay below a fifth of their time, go unregistered.

The visitor writes down the cost, rounded, under a definition the visitor picks, and only GAO's annual sample of about 100 reports is checked against records. A $5,700 bill is reported as $10,000; a $4,000 one shows up only as a checked "less than $5,000" box, which counts as zero.

And the building invites some visitors without calling them visitors: agencies ask for comments on proposed rules and committees ask for testimony, and neither counts as lobbying. Opponents on one bill also arrive together on the next: hospitals and insurers split over site-neutral payment and stood together on the premium credits.

What people argue about

Whether industry money compromises patient groups. One side: funding pays for research, patient services and education that patients want, most large groups keep it a small share of revenue (1.8% at the Alzheimer's Association, about 5% at the American Heart Association), and patients and companies often want the same things, such as faster approval and coverage of new treatments. Groups describe firewalls: the National Multiple Sclerosis Society told the Senate Finance Committee in 2022 that it takes no drug-company money for its advocacy, and Patients Rising says its funding doesn't determine its positions. The other: the 2017 survey counted only pressure groups were willing to report, and the NEJM study's authors note that groups' own disclosures likely understate industry support; the studies that compared positions found funded groups generally sided with their sponsors; and silence is a position too. KFF Health News found that in 2022, when Congress passed Medicare price negotiation, the American Cancer Society Cancer Action Network took no position and the American Heart Association said nothing about it, while the American Diabetes Association supported it. The Cancer Action Network told KFF the policy's effect on cancer patients' access and costs was unclear, and the Heart Association that its industry funds don't influence its advocacy. Public Citizen, an advocacy group that supports negotiation, counted pharmaceutical ties at 54 of the 74 groups that signed a letter backing the EPIC Act. We found no peer-reviewed study that links funding to positions across groups on recent bills.

Whether lobbying money buys outcomes. One side: the biggest spenders lose often, as drugmakers did on negotiation and PBMs on the 2026 law; spending buys a hearing, which every side can get; and in the largest study, resources explained little of who won. The other: the high returns Kang found mean small changes in the odds are worth a great deal; many wins are details, like extensions of a payment rule, that draw little notice; and studies of outcomes can't count the bills that never came up. Both rely partly on what can't be measured.

See also

Sources

The weekly digest

One email on Monday mornings: the week's new articles and charts, the numbers that moved most, and what comes out in the week ahead. No ads, and no tracking of opens or clicks.

Past issuesHow addresses are kept